A Brief History of the Pneumococcus in Biomedical Research: A Panoply of Scientific Discovery

Clinical Infectious Diseases

Volumn 17, Issue 5, 1993, Pages 913-924

  Watson, David A ^a,b   Musher, Daniel M ^a,b   Jacobson, James W ^a,b   Verhoef, Jan ^a,b  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PENICILLIN G; PNEUMOCOCCUS VACCINE;

BACTERIAL VIRULENCE; DRUG EFFICACY; DRUG SAFETY; HUMORAL IMMUNITY; IMMUNOSTIMULATION; MEDICAL RESEARCH; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS PNEUMONIAE;

ANIMAL; ANTIBIOTICS; HISTORY OF MEDICINE, 19TH CENT.; HISTORY OF MEDICINE, 20TH CENT.; HUMAN; PNEUMOCOCCAL INFECTIONS; RESEARCH; STREPTOCOCCUS PNEUMONIAE; SUPPORT, U.S. GOV'T, NON-P.H.S.; VIRULENCE;

EID: 0027372678     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/clinids/17.5.913     Document Type: Article

References (159)

1. Pasteur L. Note sur la maladie nouvelle provoquee par la salive d’un enfant mort de la rage. Bulletin de l’Academie de Medicine (Paris) [series 2] 1881;10:94-103.
2. Pasteur L, ChAmberland MM, Roux. Sur une maladie nouvelle, provoquee par la salive d’un enfant mort de la rage. Compt Rend Acad d sci 1881;92:159-65.
3. Sternberg GM. A fatal form of septicaemia in the rabbit, produced by the subcutaneous injection of human saliva. Annual Reports of the National Board of Health 1881a;3:87-108.
4. Sternberg GM. A fatal form of septicaemia in the rabbit, produced by the subcutaneous injection of human saliva. National Board of Health Bulletin 1881b;2:781-3.
5. Klebs E. Beitrage zur Kenntniss der Schistomyceten. VII. Die Monadinen. Archiv flir Experimentelle Pathologie und Pharmakologie (Leipzig) 1875;4:409-88.
6. Eberth CJ. Zur Kenntniss der mykotischen Processe. Deutsches Archly fur Klinische Medizin (Leipzig) 1880;28:1-42.
7. Sternberg GM. The pneumonia-coccus of Friedlander (Micrococcus Pasteuri. Sternberg). Am J Med Sci 1885;90:106-23.
8. Fraenkel A. Weitere Beitrage zur Lehre von den Mikrococcen der genuinen fibrinosen Pneumonie. Zeitschrift ftir Klinische Medicin 1886b;11:437-58.
9. Winslow CEA, Broadhurst J, Buchanan RE, Krumwiede C, Rogers LA, Smith GH. The families and genera of the bacteria: final report of the committee of the Society of American Bacteriologists on characterization and classification of bacterial types. J Bacteriol 1920;5:191-229.
10. Weichselbaum A. Aetiologie und pathologische Anatomie der akuten lungenentzundungen. Wiener Medizinische Wochenschrift 1886a;36:1301-5.
11. Weichselbaum A. Aetiologie und pathologische Anatomie der akuten lungenentzundungen. Wiener Medizinische Wochenschrift 1886b;36:1339-44.
12. Weichselbaum A. Aetiologie und pathologische Anatomie der akuten lungenentzundungen. Wiener Medizinische Wochenschrift 1886c;36:1367-71.
13. Weichselbaum A. Ueber die Aetiologie der acuten Lungen- und Rippenfellentzundungen. Medizinische JahrbUcher [series 3] 1886d: 483-554.
14. Deibel RH, Seeley HW. Family: Streptococcaceae. Fam. nov. In: Buchanan RE, Gibbons NE, eds. Bergy’s manual of determinative bacteriology. 8th ed. Baltimore: Williams & Wilkins, 1974: 490-517.
15. Friedlander C. Die Mikrokokken der Pneumonie. Fortschritte der Medizin (Munchen) 1883b: 1:715-33.
16. Talamon C. Coccus de la pneumonie. Bulletin de la Societe Anatomique de Paris 1883;58:475-81.
17. Fraenkel A. Die genuine Pneumonie. Verh Cong Inn Med 1884;3: 17-31.
18. Fraenkel A. Bakteriologische Mittheilungen. Zeitschrift fur Klinische Medicin 1885;10:401-61.
19. Netter. De la meningite due au pneumocoque (avec ou sans pneumonie). Archives Generales de Medecine [series 7] 1887;19:257-77, 434-55.
20. Zaufal E. Mikroorganismen im Secrete der Otitis media acuta. Prager Medicinische Wochenschrift 1887;12:225-7.
21. Austrian R. Pneumococcus: the first one hundred years. Rev Infect Dis 1981;3:183-9.
22. Austrian R. Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Rev Infect Dis 1981;3(suppl):S1-17.
23. Gram C. Ueber die isolierte Farbung der Schizomyceten in Schnittund Trockenpraparaten. Fortschr Med 1884;2:185-9.
24. Klemperer G, Klemperer F. Versuche uber Immunisirung und Heilung bei der Pneumokokkeninfection. Berliner Klinische Wochenschrift 1891a;28:869-75.
25. Klemperer G, Klemperer F. Versuche Ober Immunisirung und Heilung bei der Pneumokokkeninfection. Berliner Klinische Wochenschrift 1891b;28:833-5.
26. Issaeff B. Contribution a l’etude de l’immunite acquise contre le pneumocoque. Annales de l’Institut Pasteur 1893;7:260-79.
27. Metchnikoff E. Etudes sur l’immunite. 4 memoire. L’immunite des cobayes vaccines contre le vibrio Metchnikowii. Annales de l’Institut Pasteur 1891;5:465-78.
28. Neufeld F. Ueber die Agglutination der Pneumokokken und uber die Theorien der Agglutination. Zeitschrift fur Hygiene und Infektionskrankheiten (Leipzig) 1902;40:54-72.
29. Lund E. Laboratory diagnosis of Pneumococcus infections. Bull World Health Organ 1960;23:5-13.
30. Neufeld F, Rimpau W. Ueber die Antikorper des streptokokken- und pneumokokken-Immunserums. Deutsche Medicinische Wochenschrift 1904;30:1458-60.
31. Dubos R, Avery OT. Decomposition of the capsular polysaccharide of pneumococcus type III by a bacterial enzyme. J Exp Med 1931;54:51-71.
32. Avery OT, Dubos R. The protective action of a specific enzyme against type III pneumococcus infections in mice. J Exp Med 1931;54:73-89.
33. Francis T Jr, Terrell EE, Dubos R, Avery OT. Experimental type III pneumococcus pneumonia in monkeys: II. Treatment with an enzyme which decomposes the specific capsular polysaccharide of pneumococcus type III. J Exp Med 1934;59:641-68.
34. Ward HK, Enders J F. An analysis of the opsonic and tropic action of normal and immune sera based on experiments with the pneumococcus. J Exp Med 1933;57:527-47.
35. Johnston RB, Klemperer MR, Alper CA, Rosen FS. The enhancement of bacterial phagocytosis by serum: the role of complement components and two cofactors. J Exp Med 1969;129:1275-90.
36. Winkelstein JA. Complement and the host’s defense against the pneumococcus. CRC Crit Rev Microbiol 1984;11:187-208.
37. Janoff EN, Breiman RF, Daley CL, Hopewell PC. Pneumococcal disease during HIV infection: epidemiologic, clinical, and immunologic perspectives. Ann Intern Med 1992;117:314-24.
38. Neufeld F, Haendel L. Weitere Untersuchungen uber Pneumokokken- Heilsera. III. Mitteilung. Arbeiten aus dem Kaiserlichen Gesundheitsamte 1910;34:293-304.
39. Dochez AR, Gillespie U. A biologic classification of pneumococci by means of immunity reactions. JAMA 1913;61:727-32.
40. Lister FS. Specific serological reactions with pneumococci from different sources. Publications of the South African Institute for Medical Research 1913;1:1-14.
41. Lister FS. An experimental study of prophylactic inoculation in the rabbit and in man. Publications of the South African Institute for Medical Research 1916;1:231-87.
42. Hanes FM. An immunological study of Pneumococcus mucosus. J Exp Med 1914;19:38-51.
43. Knecht JC, Schiffman G, Austrian R. Some biological properties of pneumococcus type 37 and the chemistry of its capsular polysaccharide. J Exp Med 1970;132:475-87.
44. van Dam JEG, Fleer A, Snippe H. Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides. Antonie Van Leeuwenhoek 1990;58:1-47.
45. Dochez AR, Avery OT. Soluble substance of pneumococcus origin in the blood and urine during lobar pneumonia. Proc Soc Exp Biol Med 1917;14:126-7.
46. Heidelberger M, Avery OT. The soluble specific substance of pneumococcus. J Exp Med 1923;38:73-9.
47. Heidelberger M. Immunologically specific polysaccharides. Chemical Reviews 1927;3:403-23.
48. Dubos RJ. The professor, the institute, and DNA. New York: The Rockefeller University Press, 1976.
49. Wright AE, Morgan WP, Colebrook L, Dodgson RW. Observations on prophylactic inoculation against pneumococcus infections, and on the results which have been achieved by it. Lancet 1914;1:1-10, 87-95.
50. Heffron R. Pneumonia: with special reference to pneumococcus lobar pneumonia. Cambridge, MA: Harvard University Press, 1979.
51. Dowling HF. Fighting infection: conquests of the twentieth century. Cambridge, MA: Harvard University Press, 1977.
52. Felton LD, Baily GH. Biologic significance of the soluble specific substances of pneumococci. J Infect Dis 1926;38:131-44.
53. Francis T, Tillett WS. Cutaneous reactions in pneumonia: the development of antibodies following the intradermal injection of typespecific polysaccharide. J Exp Med 1930;52:573-85.
54. Finland M. Sutliff WD. Specific antibody response of human subjects to intracutaneous injection of pneumococcal products. J Exp Med 1932;55:853-65.
55. Finland M, Dowling HF. Cutaneous reactions and antibody response to intracutaneous injections of pneumococcus polysaccharides. J Immunol 1935;29:285-99.
56. Finland M, RuegseggerJM. Immunization of human subjects with the specific carbohydrates of type III and the related type VIII pneumococcus. J Clin Invest 1935;14:829-32.
57. Finland M, Brown JW. Reactions of human subjects to the injection of purified type specific pneumococcus polysaccharides. J Clin Invest 1938;17:479-88.
58. Smillie WG, Warnock GH, White Hi. A study ofa type I pneumococcus epidemic at the state hospital at Worcester, Mass. Am J Public Health 1938;28:293-302.
59. Felton LD. Studies on immunizing substances in pneumococci: VII. Response in human beings to antigenic pneumococcus polysaccharides, types I and II. Public Health Rep 1938;53:1855-77.
60. MacLeod CM, Hodges RG, Heidelberger M, Bernhard WG. Prevention of pneumococcal pneumonia by immunization with specific capsular. polysaccharides. J Exp Med 1945;82:445-65.
61. Heidelberger M, MacLeod CM, di Lapi MM. The human antibody response to simultaneous injection of six specific polysaccharides of pneumococcus. J Exp Med 1948;88:369-72.
62. Kaufman P. Pneumonia in old age: active immunization against pneumonia with pneumococcus polysaccharide; results of a six year study. Arch Intern Med 1947;79:518-31.
63. Austrian R. Pneumococcal infection and pneumococcal vaccine. N Engl J Med 1977;297:938-9.
64. Austrian R, Douglas RM, Schiffman G. et al. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 1976;89:184-94.
65. Robbins JB, Austrian R, Lee C-J, et al. Considerations for formulating the second generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983;148:1136-59.
66. Musher DM, Watson DA, Dominguez EA. Pneumococcal vaccination: work to date and future prospects. Am J Med Sci 1990;300:45-52.
67. Bruyn GAW, Zegers BJM, van Furth R. Mechanisms of host defense against infection with Streptococcus pneumoniae. Clin Infect Dis 1992;14:251-62.
68. Broome CV, Breiman RF. Pneumococcal vaccine: past, present, and future. N Engl J Med 1991;325:1506-8.
69. Bolan G, Broome CV, Facklam RR, Plikaytis BD, Fraser DW, Schlech WF. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med 1986;104:1-6.
70. Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988;108:653-7.
71. Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med 1984;101:325-30.
72. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453-60.
73. Makela PH, Sibakov M, Herva E, et al. Pneumococcal vaccine and otitis media. Lancet 1980;2:547-51.
74. Simberkoff MS, El Sadr W, Schiffman G, Rahal JJ. Streptococcus pneumoniae infections and bacteremia in patients with acquired immune deficiency syndrome with report of a pneumococcal vaccine failure. Am Rev Respir Dis 1984;130:1174-6.
75. Rodriguez-Barradas MC, Musher DM, Lahart C, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23- valent pneumococcal vaccine. J Infect Dis 1992;165:553-6.
76. Beuvery EC, van Rossum F, Nagel J. Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates. Infect Immun 1982;37:15-22.
77. Lin KT, Lee CJ. Immune response of neonates to pneumococcal polysaccharide- protein conjugate. Immunology 1982;46:333-42.
78. Schneerson R, Robbins JB, Chu C, et al. Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide- protein conjugates. Infect Immun 1984;45:582-91.
79. Schneerson R, Robbins JB, Park JC, et al. Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide- tetanus toxoid conjugates. Infect Immun 1986;52:519-28.
80. Morganroth J, Levy R. Chemotherapie der Pneumokokkeninfektion. Berliner Klinische Wochenschrift 1911;48:1560-1.
81. Morganroth J, Kaufmann M. Arzneifestigkeit bei Bakterien (Pneumokokken). Zeitschrift fur Immunitatsforschung and Experimentelle Therapie 1912;15:610-24.
82. Watson DA, Musher DM. Characterization of resistance to optochin among isolates of Streptococcus pneumoniae [abstract no C-19]. In: Program and abstracts of the 92nd general meeting of the American Society for Microbiology. Washington, DC: American Society for Microbiology, 1992.
83. White B. The biology of pneumococcus: the bacteriological, biochemical, and immunological characters and activities of Diplococcus pneumoniae. Cambridge, MA: Harvard University Press, 1979.
84. Moore HF, Chesney AM. A study of ethylhydrocuprein (optochin) in the treatment of acute lobar pneumonia. Arch Intern Med 1917;19:611-82.
85. Finland M, Sutliff WD. Specific cutaneous reactions and circulating antibodies in the course of lobar pneumonia: II. Cases treated with antipneumococcic sera. J Exp Med 1931;54:653-67.
86. Felton LD. A study of the isolation and concentration of the specific antibodies of antipneumococcus sera. Boston Medical and Surgical Journal 1924;190:819-25.
87. Barach AL. Immune transfusion in lobar pneumonia. Am J Med Sci 1931;182:811-21.
88. Whitby LEH. Chemotherapy of pneumococcal and other infections with 2-(p-aminobenzenesulphonamido) pyridine. Lancet 1938;1: 1210-2.
89. Evans GM, Gaisford WF. Treatment of pneumonia with 2-(paminobenzenesulphonamido) pyridine. Lancet 1938;2:14-9.
90. Tillett WS, Cambier MJ, Harris WH. Sulfonamide-fast pneumococci: a clinical report of two cases of pneumonia together with experimental studies on the effectiveness of penicillin and tyrothricin against sulfonamide-resistant strains. J Clin Invest 1943;22: 249-55.
91. Fleming A. On the antibacterial action of cultures of a Penicillium with special reference to their useful isolation of B. influenzae. British Journal of Experimental Pathology 1929;10:226-36.
92. Abraham EP, Gardner AD, Chain E, et al. Further observations on penicillin. Lancet 1941;2:177-89.
93. Dubos RJ. Studies on a bactericidal agent extracted from a soil bacillus: II. Protective effect of the bactericidal agent against experimental pneumococcus infections in mice. J Exp Med 1939;70:11-7.
94. Hotchkiss RD, Dubos RJ. Fractionation of the bactericidal agent from cultures of a soil bacillus [letter]. J Biol Chem 1940;132:791-2.
95. MacLeod CM, Mirick GS, Curnen EC. Toxicity for dogs of a bactericidal substance derived from a soil bacillus. Proc Soc Exp Biol Med 1940;43:461-3.
96. Chain E, Jennings MA, Florey HW, et al. Penicillin as a chemotherapeutic agent. Lancet 1940;2:226-8.
97. Keefer CS, Blake FG, Marshall EK, Lockwood JS, Wood WB. Penicillin in the treatment of infections: a report of 500 cases. J AMA 1943;122:1217-24.
98. Tillett WS, Cambier MJ, McCormack JE. The treatment of lobar pneumonia and pneumococcal empyema with penicillin. Bull N Y Acad Sci 1944;20:142-78.
99. Mufson MA. Streptococcus pneumoniae. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990.
100. McKee CM, Houck CL. Induced resistance to penicillin of cultures of staphylococci, pneumococci, and streptococci. Proc Soc Exp Biol Med 1943;53:33-4.
101. Schmidt LH, Sesler CL. Development of resistance to penicillin by pneumococci. Proc Soc Exp Biol Med 1943;52:353-7.
102. Hansman D, Bullen MM. A resistant pneumococcus [letter]. Lancet 1967;2:264-5.
103. Appelbaum PC, Koornhof HJ, Jacobs M, et al. Multiple-antibiotic resistance of pneumococci: South Africa. MMWR 1977;26:285-6.
104. Appelbaum PC, Bhamjee A, Scragg JN, Hallett AF, Bowen AJ, Cooper RC. Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet 1977;2:995-7.
105. Jacobs MR, Koornhof HJ, Robins-Browne RM, et al. Emergence of multiply resistant pneumococci. N Engl J Med 1978;299:735-40.
106. Waxman DJ, StromingerJL. Penicillin-binding proteins and the mechanism of action of beta-lactam antibiotics. Annu Rev Biochem 1983;52:825-69.
107. Spratt BG. Properties of the penicillin-binding proteins of Escherichia coli K12. Eur J Biochem 1977;72:341-52.
108. Eagle H. The binding of penicillin in relation to its cytotoxic action: I. Correlation between the penicillin sensitivity and combining activity of intact bacteria and cell-free extracts. J Exp Med 1954;99:207-26.
109. Eagle H. The binding of penicillin in relation to its cytotoxic action: II. The reactivity with penicillin of resistant variants of streptococci, pneumococci, and staphylococci. J Exp Med 1954;100:103-15.
110. Hakenbeck R, Tarpay M, Tomasz A. Multiple changes of penicillinbinding proteins in penicillin-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1980;17: 364-71.
111. Zighelboim S, Tomasz A. Penicillin-binding proteins of multiply antibiotic- resistant South African strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 1980;17:434-42.
112. Hakenbeck R, Ellerbrok H, Briese T, Handwerger S, Tomasz A. Penicillin- binding proteins of penicillin-susceptible and -resistant pneumococci: immunological relatedness of altered proteins and changes in peptides carrying the /3-lactam binding site. Antimicrob Agents Chemother 1986;30:553-8.
113. Hakenbeck R, Ellerbrok H, Tornette 5, van de Rijn I. Common antigenic determinants of pneumococcal penicillin-binding protein (PBP) la and Streptococcus pyogenes PBP 2. FEMS Microbiol Lett 1987;48:171-4.
114. Chalkley U, Koornhof HJ. Penicillin-binding proteins of Streptococcus pneumoniae. J Antimicrob Chemother 1988;22:791-800.
115. Dowson CG, Hutchinson A, Spratt BG. Extensive re-modelling of the transpeptidase domain of penicillin-binding protein 2B of a penicillin- resistant South African isolate of Streptococcus pneumoniae. Mol Microbiol 1989;3:95-102.
116. Jabes D, Nachman S, Tomasz A. Penicillin-binding protein families: evidence for the clonal nature of penicillin resistance in clinical isolates of pneumococci. J Infect Dis 1989;159:16-25.
117. Dowson CG, Hutchison A, Woodford N, Johnson AP, George RC, Spratt BG. Penicillin-resistant viridans streptococci have obtained altered penicillin-binding protein genes from penicillin-resistant strains of Streptococcus pneumoniae. Proc Natl Acad Sci USA 1990;87:5858-62.
118. Hakenbeck R, Laible G, Briese T, et al. Highly variable penicillinbinding proteins in penicillin-resistant strains of Streptococcus pneumoniae. In: Dunny GM, Cleary PP, McKay LL, eds. Genetics and molecular biology of streptococci, lactococci, and enterococci. Washington, DC: American Society for Microbiology, 1991:92-5.
119. Dowson CG, Hutchison A, Brannigan JA, et al. Horizontal transfer of penicillin-binding protein genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae. Proc Natl Acad Sci USA 1989;86:8842-6.
120. Coffey TJ, Dowson CG, Daniels M, et al. Horizontal transfer of multiple penicillin-binding protein genes, and capsular biosynthetic genes, in natural populations of Streptococcus pneumoniae. Mol Microbiol 1991;5:2255-60.
121. Mutioz R, Coffey TJ, Daniels M, et al. Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae. J Infect Dis 1991;164:302-6.
122. Latorre C, Juncosa T, Sanfeliu I. Antibiotic resistance and serotypes of 100 Streptococcus pneumoniae strains isolated in a children’s hospital in Barcelona, Spain. Antimicrob Agents Chemother 1985;28: 357-9.
123. Klugman KP, Koornhof HJ. Drug resistance patterns and serogroups or serotypes of pneumococcal isolates from cerebrospinal fluid or blood, 1979-1986. J Infect Dis 1988;158:956-64.
124. Marton A, Gulyas M, Munoz R, Tomasz A. Extremely high incidence of antibiotic resistance in clinical isolates of Streptococcus pneumoniae in Hungary. J Infect Dis 1991;163:542-8.
125. Stryker LM. Variations in the pneumococcus induced by growth in immune serum. J Exp Med 1916;24:49-68.
126. Griffith F. The influence of immune serum on the biological properties of pneumococci. In: Reports on public health and medical subjects. No. 18. Bacteriological studies. London: His Majesty’s Stationery Office, 1923:1-13.
127. Arkwright JA. Variation in bacteria in relation to agglutination both by salts and by specific serum. J Pathol Bacteriol 1921;24:36-60.
128. Griffith F. The significance of pneumococcal types. J Hyg 1928;27:113-59.
129. Neufeld F, Levinthal W. Beitrage zur Variabilitdt der Pneumokokken. Zeitschrift air Immunitatsforschung and Experimentelle Therapie 1928;55:324-40.
130. Dawson MH. The interconvertibility of "R" and "S" forms of pneumococcus. J Exp Med 1928;47:577-91.
131. Dawson MH, Sia RHP. In vitro transformation of pneumococcal types: I. A technique for inducing transformation of pneumococcal types in vitro. J Exp Med 1931;54:681-99.
132. Dawson MH, Warbasse A. Further observations on the transformation of type-specific pneumococci by in vitro procedures. Proc Soc Exp Biol Med 1931;29:149-51.
133. Sia RHP, Dawson MH. In vitro transformations of pneumococcal types: II. The nature of the factor responsible for the transformation of pneumococcal types. J Exp Med 1931;54:701-10.
134. Alloway JL. The transformation in vitro of R pneumococci into S forms of different specific types by the use of filtered pneumococcus extracts. J Exp Med 1932;55:91-9.
135. Alloway JL. Further observations on the use of pneumococcus extracts in effecting transformation of type in vitro. J Exp Med 1933;57:265-78.
136. McCarty M. The transforming principle: discovering that genes are made of DNA. New York: WW Norton, 1985.
137. Avery OT, MacLeod CM, McCarty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types: induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J Exp Med 1944;79:137-57.
138. Hotchkiss RD. Gene, transforming principle, and DNA. In: Cairns J, Stent G, Watson JD, eds. Phage and the origins of molecular biology. Cold Spring Harbor, NY: Cold Spring Harbor Press, 1966.
139. McCarty M, Avery OT. Studies on the chemical nature of the substance inducing transformation of pneumococcal types: II. Effect of desoxyribonuclease on the biological activity of the transforming substance. J Exp Med 1946;83:89-96.
140. Hotchkiss RD. Transfer of penicillin resistance in pneumococci by the desoxyribonucleate derived from resistant cultures. Cold Spring Harb Symp Quant Biol 1951;16:457-61.
141. Watson JD. The double helix: a personal account of the discovery of the structure of DNA. New York: Atheneum, 1968.
142. Austrian R, Bernheimer HP. Simultaneous production of two capsular polysaccharides by pneumococcus: I. Properties ofa pneumococcus manifesting binary capsulation. J Exp Med 1959;110:571-84.
143. Austrian R, Bernheimer HP, Smith EEB, Mills GT. Simultaneous production of two capsular polysaccharides by pneumococcus: II. The genetic and biochemical bases of binary capsulation. J Exp Med 1959;110:585-602.
144. Ravin AW. Reciprocal capsular transformations of pneumococci. J Bacteriol 1959;77:296-309.
145. Orskov I, Sharma V, Orskov F. Genetic mapping of the K I and K4 antigens (L) of Escherichia coli. Acta Pathol Microbiol Scand [B] 1976;84:125-31.
146. Silver RP, Vann WF, Aaronson W. Genetic and molecular analyses of Escherichia coli Kl antigen genes. J Bacteriol 1984;157:568-75.
147. Boulnois GJ, Roberts IS, Hodge R, Hardy KR, Jann KB, Timmis KN. Analysis of the K1 capsule biosynthesis genes of Escherichia coll. definition of three functional regions for capsule production. Mol Gen Genet 1987;208:242-6.
148. Moxon ER, Deich RA, Connelly C. Cloning of chromosomal DNA from Haemophilus influen:ae: its use for studying the expression of type b capsule and virulence. J Clin Invest 1984;73:298-306.
149. Hoiseth SK, Moxon ER, Silver RP. Genes involved in Haemophilus influenzae type b capsule expression are part of an 18-kilobase tandem duplication. Proc Natl Acad Sci USA 1986;83:1106-10.
150. Kroll JS, Hopkins I, Moxon ER. Capsule loss in Haemophilus influenzae type b occurs by recombination-mediated disruption of a gene essential for polysaccharide export. Cell 1988;53:347-56.
151. Kroll JS, Zamze S, Loynds B, Moxon ER. Common organization of chromosomal loci for production of different capsular polysaccharides in Haemophilus influenzae. J Bacteriol 1989;171:3343-7.
152. Watson DA, Musher DM. Interruption of capsule production in Streptococcus pneumoniae serotype 3 by insertion of transposon Tn9/6. Infect Immun 1990;58:3135-8.
153. Watson DA, Musher DM, Jacobson JW. Initial characterization of a cloned sequence required for encapsulation of Streptococcus pneumoniae serotype 3 [abstract no B-165]. In: Program and abstracts of the 91st annual meeting of the American Society for Microbiology. Washington, DC: American Society for Microbiology, 1991.
154. Boulnois GJ. Pneumococcal proteins and the pathogenesis of disease caused by Streptococcus pneumoniae. J Gen Microbiol 1992; 138:249-59.
155. Briles DE, Crain MJ, Gray BM, Forman C, Yother J. Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae. Infect Immun 1992;60: 111-6.
156. McDaniel LS, Scott G, Widenhofer K, Carroll JM, Briles DE. Analysis of a surface protein of Streptococcus pneumoniae recognised by protective monoclonal antibodies. Microb Pathog 1986;1:519-31.
157. Yother J, McDaniel LS, Crain MJ, Talkington DF, Briles DE. Pneumococcal surface protein A: structural analysis and biological significance. In: Dunny GM, Cleary PP, McKay LL, eds. Genetics and molecular biology of streptococci, lactococci, and enterococci. Washington, DC: American Society for Microbiology, 1991:88-91.
158. McDaniel LS, Sheffield JS, Delucchi P, Briles DE. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect Immun 1991;59:222-8.
159. Martin B, Humbert O, Camara M, et al. A highly conserved repeated DNA element located in the chromosome of Streptococcus pneumoniae. Nucleic Acids Res 1992;20:3479-83.